WAM
MDGL icon

Wealthspire Advisors (Maryland)’s Madrigal Pharmaceuticals MDGL Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-6
Closed -$1K – 1365
2019
Q1 		$1K Hold
6
– – ﹤0.01% 2356
2018
Q4 		$1K Sell
6
-1
-14% -$155 ﹤0.01% 2293
2018
Q3 		$1K Hold
7
– – ﹤0.01% 2297
2018
Q2 		$2K Hold
7
– – ﹤0.01% 2170
2018
Q1 		$1K Sell
7
-1
-13% -$123 ﹤0.01% 2357
2017
Q4 		$1K Hold
8
– – ﹤0.01% 2302
2017
Q3 		$0 Buy
+8
New +$150 ﹤0.01% 2375

Other funds holding MDGL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s MDGL Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2019, closing a stake of 6 shares — an estimated $1K sold.

Wealthspire Advisors (Maryland) first reported a position in MDGL in Q3 2017 and held it in 7 quarters. The position peaked at $2K in Q2 2018. 116 funds tracked by Wall St. Rank hold MDGL as of Q2 2019.

  • Wealthspire Advisors (Maryland) reported no remaining Madrigal Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 6 Madrigal Pharmaceuticals shares in Q2 2019, an estimated $1K.
  • Wealthspire Advisors (Maryland) first reported a position in Madrigal Pharmaceuticals in Q3 2017 and held it in 7 quarters.
  • Wealthspire Advisors (Maryland)'s Madrigal Pharmaceuticals position peaked at $2K in Q2 2018.
  • 116 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.